natgillin/translations-raw huggingface dataset:
Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone. 
Zabilježeno je da istovremena primjena pioglitazona s rifampicinom (induktor citokroma P450 2C8) dovodi do sniženja AUC-a pioglitazona za 54%.
Titanium dioxide (E171). 
Film ovojnica hipromeloza makrogol 8000 talk titanijev dioksid (E171)
- a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034 - a significant reduction of the absolute risk of any diabetes-related mortality: metformin 7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017 - a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patient-years (p=0.021) 
Prospektivno randomizirano (UKPDS) ispitivanje ustanovilo je dugotrajnu korist intenzivne kontrole glukoze u krvi kod šećerne bolesti tipa 2. Analiza rezultata za bolesnike s prekomjernom tjelesnom težinom koji su nakon neuspjeha liječenja samo dijetom bili liječeni metforminom pokazala je: - značajno sniženje apsolutnog rizika za sve komplikacije šećerne bolesti u skupini koja je primala metformin (29,8 događaja na 1000 bolesničkih godina) u odnosu na skupinu liječenu samo dijetom (43,3 događaja na 1000 bolesničkih godina), p = 0,0023, i kombinirane skupine na sulfonilureji i inzulinskoj monoterapiji (40,1 događaja na 1000 bolesničkih godina), p = 0,0034
Maximum daily dose is 45 mg 
Bez prilagodbe doze Maksimalna dnevna doza iznosi 45 mg.
Competact may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. 
Competact može uzrokovati vrlo rijetku, ali vrlo ozbiljnu nuspojavu koja se naziva laktacidoza,
Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone. 
Zabilježeno je da istovremena primjena pioglitazona s gemfibrozilom (inhibitor citokroma P450 2C8) rezultira trostrukim porastom AUC-a pioglitazona.
Package leaflet: Information for the patient Competact 15 mg/850 mg film-coated tablets pioglitazone/metformin hydrochloride 
Uputa o lijeku: Informacije za bolesnika Competact 15 mg/850 mg filmom obložene tablete pioglitazon/metforminklorid
Posology 
Primjenu
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Competact. 
Manje često (može se javiti u do 1 na 100 osoba) se u bolesnika koji su uzimali Competact razvio karcinom mokraćnog mjehura.
Competact 15 mg/850 mg tablets pioglitazone/metformin hydrochloride 
Competact 15 mg/850 mg tablete pioglitazon/metforminklorid
Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD05. 
5.1 Farmakodinamička svojstva Farmakoterapijska skupina: Lijekovi za primjenu kod šećerne bolesti, kombinirani peroralni lijekovi za sniženje glukoze u krvi.
(ACE) inhibitors and angiotensin II receptor antagonists) 
- određene lijekove za liječenje povišenog krvnog tlaka inhibitori angiotenzin-konvertirajućeg enzima (ACE) i antagonisti receptora angiotenzina II)
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. 
U razdoblju nakon stavljanja lijeka u promet, kod uzimanja tiazolidindiona, uključujući pioglitazon, zabilježeni su slučajevi novonastalog dijabetičkog makularnog edema sa smanjenjem oštrine vida.
Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve. 
Bolesnike, osobito one sa smanjenom srčanom rezervom, treba pratiti zbog moguće pojave znakova i simptoma zatajenja srca, povećanja tjelesne težine ili pojave otoka.
Thu. 
C.
If you stop using Competact, your blood sugar may go up. 
šećer u krvi Vam se može povisiti.
Neoplasms benign, malignant and unspecified (including cysts and polyps) 
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe) rak mokraćnog mjehura manje često manje često
In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4). 
liječnici koji propisuju lijek trebaju rutinski kontrolirati održanost koristi primjene pioglitazona (vidjeti dio 4.4).
Vitamin B12 absorption decreased2 
Poremećaji metabolizma i prehrane snižena apsorpcija vitamina B122
Competact 15 mg/850 mg film-coated tablets pioglitazone/metformin hydrochloride 
Competact 15 mg/850 mg filmom obložene tablete pioglitazon/metforminklorid
At the initiation of the treatment abdominal pain, diarrhoea, loss of appetite, nausea and vomiting may occur, these reactions are very common but usually disappear spontaneously in most cases. 
Na početku liječenja mogu se javiti bol u trbuhu, proljev, gubitak apetita, mučnina i povraćanje.
Decreased renal function in elderly patients is frequent and asymptomatic. 
Stariji bolesnici često imaju smanjenu funkciju bubrega ali bez simptoma.
Weight gain 
- povećanje tjelesne težine
Maximum daily dose is 2,000 mg. 
45-59 Maksimalna dnevna doza je 2000 mg
It is especially important to mention the following: - gemfibrozil (used to lower cholesterol) - rifampicin (used to treat tuberculosis and other infections) - cimetidine (used to reduce stomach acid) - glucocorticoids (used to treat inflammation) - beta-2-agonists (used to treat asthma) - medicines which increase urine production (diuretics) - medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as ibuprofen and celecoxib) - certain medicines for the treatment of high blood pressure (angiotensin-converting enzyme 
- lijekove koji povećavaju stvaranje mokraće (diuretici) - lijekove koji se primjenjuju za liječenje boli i upale (NSAIL i COX-2-inhibitori, kao što su ibuprofen i celekoksib)
Mon. 2 
Uto 2
Very common (may affect more than 1 in 10 people) - stomach ache - feeling sick (nausea) - vomiting - diarrhoea - loss of appetite 
Često (mogu se javiti u 1 na 10 osoba) - lokalizirano oticanje (edem)
Film coat 
Prijelomi kostiju6
Mon. 1 
Uto 1
Hepatic impairment 
- poremećen vid
Competact must therefore not be used in women who are breast-feeding (see section 4.3). 
Nije poznato bi li dojenje dovelo do izloženosti dojenčeta ovom lijeku pa se stoga Competact ne smije primjenjivati u dojilja (vidjeti dio 4.3).
Marketing authorisation holder 
NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET
Musculoskeletal and connective tissue disorders bone fracture6 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 - Cardiac failure or history of cardiac failure (NYHA stages I to IV) - Current bladder cancer or a history of bladder cancer - Uninvestigated macroscopic haematuria - Acute or chronic disease which may cause tissue hypoxia such as cardiac or respiratory failure, 
- akutnom ili kroničnom bolešću koja može prouzročiti hipoksiju tikva, kao što je srčano ili respiratorno zatajenje, nedavni infarkt miokarda, šok
recent myocardial infarction, shock - Hepatic impairment - Acute alcohol intoxication, alcoholism - Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis) - Diabetic pre-coma - Severe renal failure (GFR < 30 mL/min) 
- bilo koja vrsta akutne metaboličke acidoze (kao što je laktacidoza, dijabetička ketoacidoza) - dijabetička predkoma
Talc 
Čet
Tue. 1 
Pon 1
• If this happens, you may be able to feel these pieces on your tongue. 
• Ako se to dogodi, možda ćete osjetiti te komadiće na jeziku.
Otherwise, wait for your next dose. 
U suprotnom, čekajte svoju sljedeću dozu.
Lift here to open. 
Ovdje podići i otvoriti.
Take the other 3 capsules in the same way. 
Uzmite preostale 3 kapsule na isti način.
Some people do not get this infection until later on in their lives, while others get it very young. 
Neki ljudi tu infekciju dobiju kasnije u životu, dok je drugi dobiju vrlo mladi.
It should appear pierced and empty. 
Trebala bi biti probušena i prazna.
You then start another course. 
Zatim ćete započeti sljedeći ciklus.
The dose is the same for everyone aged 6 years and older. 
Doza je jednaka za sve u dobi od 6 i više godina.
Talk to your doctor if you are concerned about this. 
Obratite se svom liječniku ako ste zabrinuti zbog toga.
Tell your doctor or a pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. 
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući i one koje ste nabavili bez recepta.
If the capsule does not look pierced: 
Ako kapsula ne izgleda probušeno:
• Disturbed sense of taste. 
• Poremećen osjet okusa
Taking your capsules at the same time each day will help you remember when to take them. 
Ako uzimate kapsule u isto vrijeme svakoga dana, lakše ćete zapamtiti kada ih trebate uzeti.
Repeat, starting at step 5, for the remaining three capsules of the dose. 
15. Ponovite, počevši od 5-og koraka, za preostale tri kapsule koje su dio doze.
Wash and fully dry your hands. 
Operite i dobro osušite ruke.
FOUR capsules are required for ONE complete dose. 
ČETIRI kapsule su potrebne za JEDNU punu dozu.
Please check the order of medications with your doctor. 
Molimo provjerite redoslijed sa svojim liječnikom.
Occasionally, very small pieces of the capsule can get past the screen and get into your mouth. 
Povremeno vrlo mali komadići kapsule mogu proći kroz rešetku i ući Vam u usta.
You should check with your doctor if you are not sure. 
Provjerite s liječnikom ako niste sigurni.
• Please read the instructions at the end of this leaflet for more information about how to use the inhaler. 
• Molimo pročitajte upute na kraju ove upute za više informacija o načinu uporabe inhalatora.
• 7 capsule cards (one card for each day of the week). 
• 7 kartica s kapsulama (jedna kartica za svaki dan u tjednu).
Tell your doctor if you have ever had any of the following conditions: 
Obratite se svom liječniku ako ste ikada imali bilo što od sljedećeg:
The hard capsules are supplied in PVC/PA/Alu/PVC- PET/Alu blisters. 
Tvrde kapsule pakirane su u PVC/PA/Al/PVC- PET/Al blisterima.
In the active-controlled study, audiology testing was performed in selected centres accounting for about a quarter of the study population. 
U aktivno kontroliranom ispitivanju obavljeno je audiološko testiranje u odabranim centrima u otprilike četvrtine ispitivane populacije.
Cough was not related to bronchospasm. 
Kašalj nije bio povezan s bronhospazmom.
• You are now ready to inhale the capsule in 2 separate breaths (Steps 8 and 9). 
• Sada ste spremni za inhalaciju kapsule u 2 zasebna udisaja (koraci 8 i 9).
Date of first authorisation: 20 July 2011 Date of latest renewal: 18 February 2016 
Datum posljednje obnove odobrenja: 18. veljače 2016.
• Loss of voice 
• Gubitak glasa
See sections 4.4 and 5.1 regarding data in different age groups. 
Vidjeti dijelove 4.4 i 5.1 za podatke u različitim dobnim skupinama.
This means that TOBI Podhaler may not work as well as it should over time. 
To znači da TOBI Podhaler možda s vremenom neće djelovati kako bi trebao.
• It is best to leave close to 12 hours between doses, but this must be at least 6 hours 
• Najbolje je da prođe blizu 12 sati između doza, ali razmak mora biti najmanje 6 sati.
See also information on clinical benefit and tolerability in sections 4.4, 4.8 and 5.1. 
Vidjeti također informacije o kliničkoj koristi i podnošljivosti u dijelovima 4.4, 4.8 i 5.1.
What is Pseudomonas aeruginosa 
Što je Pseudomonas aeruginosa
This analysis did not show gender or age-related pharmacokinetic differences 
Ta analiza nije pokazala farmakokinetičke razlike povezane sa spolom ili dobi.
For the best results from this medicine, please use it as this leaflet instructs you. 
Za najbolje rezultate ovog lijeka, molimo primjenjujte ga u skladu s ovom uputom.
If the capsule is pierced but still contains some powder: 
Ako je kapsula probušena, ali još uvijek sadrži nešto praška:
Hold the foil close to where you are rolling back. 
Foliju držite blizu mjesta gdje je povlačite.
• The chances of the capsule breaking into pieces will be increased if the capsule is accidentally pierced more than once or if the device is not held with the mouthpiece pointing down during step 7. 
• Vjerojatnost da će se kapsula razbiti u komadiće veća je ako kapsulu slučajno probušite više od jedanput ili ako uređaj ne držite s nastavkom za usta okrenutim prema dolje tijekom koraka 7.
TOBI Podhaler should not be given to children less than 6 years old. 
TOBI Podhaler se ne smije davati djeci mlađoj od 6 godina.
Each Podhaler device and its case are used for seven days and then discarded and replaced. 
Svaki uređaj Podhaler i njegov spremnik koriste se sedam dana, a zatim se moraju baciti i zamijeniti.
• Coughing up blood (very common) 
• Iskašljavanje krvi (vrlo često)
Talk to your doctor if the cough is persistent and is a burden for you. 
Obratite se svom liječniku ako je kašalj ustrajan i ako Vam predstavlja opterećenje.
2 x monthly multipack wrapped in foil 
2 x mjesečno višestruko pakiranje zamotano u foliju
Inhale the content of 4 capsules twice a day as follows: 
Inhalirajte sadržaj 4 kapsule dvaput na dan kako slijedi:
• After this if the capsule is still full and appears not to be pierced, replace the inhaler with the reserve inhaler and repeat Steps 2, 3, 6, 7, 8, 9 and 10. 
• Nakon toga, ako je kapsula još uvijek puna i izgleda kao da nije probušena, zamijenite inhalator rezervnim inhalatorom i ponovite korake 2, 3, 6, 7, 8, 9 i 10.
• muscle weakness that lasts or becomes worse over time, a symptom mostly related to conditions such as myasthenia or Parkinson's disease. 
• slabost mišića koja traje ili se pogoršava s vremenom, simptom koji je uglavnom povezan sa stanjima kao što su mijastenija ili Parkinsonova bolest.
Do not overtighten (2). 
Pazite da ga ne navijete prečvrsto (2).
It is one of the most damaging bacteria for people with cystic fibrosis. 
To je jedna od najštetnijih bakterija za osobe sa cističnom fibrozom.
Resistance to tobramycin involves different mechanisms. 
Rezistencija na tobramicin uključuje različite mehanizme.
Consideration should be given to official guidance on the appropriate use of antibacterial agents. 
Moraju se uzeti u obzir službene smjernice za primjerenu uporabu antibakterijskih lijekova.
A difference in FEV1 response by age was noted. 
Uočena je razlika u odgovoru FEV1 prema dobi.
4 capsules = 1 dose 
4 kapsule = 1 doza
Missed doses 
Propuštena doza
Take TOBI Podhaler twice a day, every day for 28 days 
Uzimajte TOBI Podhaler dvaput na dan, svaki dan tijekom 28 dana
If you forget to take TOBI Podhaler and there are at least 6 hours to your next dose, take your dose as soon as you can. 
Ako zaboravite uzeti TOBI Podhaler, a do sljedeće doze je ostalo najmanje 6 sati, uzmite dozu čim možete.
TOBI Podhaler is administered by inhalation using the Podhaler device (see section 6.6 for detailed instructions for use). 
TOBI Podhaler se primjenjuje inhalacijom korištenjem uređaja Podhaler (vidjeti dio 6.6 za detaljne upute za uporabu).
No other inhaler may be used. 
Ne smije se koristiti nijedan drugi inhalator.
The variability in pharmacokinetic parameters was higher in sputum as compared to serum. 
Varijabilnost farmakokinetičkih parametara bila je viša u sputumu nego u serumu.
If it is empty, discard the capsule. 
Ako je prazna, uklonite kapsulu.
However, subcutaneous administration of tobramycin during organogenesis was not teratogenic nor embryotoxic. 
Međutim, potkožna primjena tobramicina tijekom organogeneze nije bila teratogena ili embriotoksična.
Otherwise, the patient should wait for the next dose and not inhale more capsules to make up for the missed dose. 
U suprotnom, bolesnik treba čekati sljedeću dozu i ne inhalirati više kapsula kako bi nadoknadio propuštenu dozu.
Tear the perforations along the length then width: see Figures (a) and (b). 
Otkinite po perforacijama prvo po dužini, a zatim po širini: vidjeti Slike (a) i (b).
Not all pack sizes may be available in your country. 
Na tržištu se ne moraju nalaziti sve veličine pakiranja.
The safety and efficacy of TOBI Podhaler in children aged under 6 years have not been established. 
Sigurnost i djelotvornost TOBI Podhalera u djece u dobi ispod 6 godina nisu ustanovljene.
It must not be administered by any other route or using any other inhaler. 
Ne smije se primjenjivati nikakvim drugim putem ili korištenjem bilo kojeg drugog inhalatora.
Each inhaler is only used for 7 days. 
Svaki se inhalator koristi samo 7 dana.
However, aminoglycosides can cause foetal harm (e.g. congenital deafness) when high systemic concentrations are achieved in a pregnant woman. 
Međutim, aminoglikozidi mogu uzrokovati oštećenje ploda (npr. kongenitalnu gluhoću) kad se u trudnice postigne visoka sistemska koncentracija lijeka.
Use this if your weekly inhaler is not functioning correctly, is wet, or has dropped on the ground. 
Upotrijebiti ga ako Vaš tjedni inhalator ne radi ispravno, ako je mokar ili ako je pao na pod.
Patients in this study had no exposure to inhaled tobramycin for at least 4 months prior to study start. 
Bolesnici u ovom ispitivanju nisu bili izloženi inhalacijskom tobramicinu najmanje 4 mjeseca prije početka ispitivanja.
However, no association was observed in either clinical study between the incidence of bronchospasm and cough events. 
Međutim, nije bila uočena nikakva povezanost u bilo kojem kliničkom ispitivanju između incidencije bronhospazma i kašlja.
Data in different age groups 
Podaci za različite dobne skupine
Once removed from the capsule card (blister), a capsule should be used immediately. 
Nakon što se izvadi iz kartice s kapsulama (blistera), kapsulu treba odmah upotrijebiti.
In the open label extensions, each additional 6 months of treatment resulted in incremental increases similar in magnitude to that observed in the 6 months of placebo-controlled studies. 
U otvorenim produžecima, svakih dodatnih 6 mjeseci liječenja rezultiralo je postupnih povećanjima, po veličini sličnim onima koja su primijećena u 6mjesečnim placebom kontroliranim ispitivanjima.
See also section 4.2. 
Vidjeti također dio 4.2.
It acts primarily by disrupting protein synthesis leading to altered cell membrane permeability, progressive disruption of the cell envelope and eventual cell death. 
Djeluje prvenstveno tako da ometa sintezu proteina, što dovodi do promjene propusnosti stanične membrane, progresivnog prekida stanične ovojnice i konačno do smrti stanice.
• if you are allergic to tobramycin, to any type of aminoglycoside antibiotic, or to any of the other ingredients of this medicine (listed in section 6). 
• ako ste alergični na tobramicin, na bilo koju vrstu aminoglikozidnih antibiotika, ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
Although the magnitude of improvements in lung function was smaller in this study, this is explained by the previous exposure of this patient population to treatment with inhaled tobramycin. 
Iako su poboljšanja plućne funkcije u ovom ispitivanju bila manja, to se objašnjava prethodnom izloženošću ove populacije bolesnika liječenju s inhalacijskim tobramicinom.
It is a very common bacterium that infects the lungs of nearly everyone with cystic fibrosis at some time during their lives. 
To je vrlo česta bakterija koja zarazi pluća gotovo svih oboljelih od cistične fibroze u nekom trenutku njihovog života.
The main resistance mechanisms are drug efflux and drug inactivation by modifying enzymes. 
Glavni mehanizmi rezistencije su izbacivanje lijeka i inaktivacija lijeka modificirajućim enzimima.
FEV1 should be measured before and after inhalation of TOBI Podhaler. 
FEV1 se treba mjeriti prije i nakon inhalacije TOBI Podhalera.
You should not take the following medicines while you are taking TOBI Podhaler: 
Ne smijete uzimati sljedeće lijekove dok uzimate TOBI Podhaler:
• Furosemide or ethacrynic acid, diuretics 
• Furosemid ili etakrinsku kiselinu, diuretike
The development of antibiotic-resistant P. aeruginosa and superinfection with other pathogens represent potential risks associated with antibiotic therapy. 
Razvoj P. aeruginosa rezistentnog na antibiotike i superinfekcija s drugim patogenima predstavljaju potencijalne rizike povezane s antibiotskom terapijom.
Basic instructions for use are given below, more detailed instructions are available from the patient leaflet. 
Osnovne upute za uporabu navedene su u nastavku, a podrobnije upute dostupne su u uputi o lijeku.
Tear along the perforations of the capsule card lengthwise then widthwise, as indicated in pictures (1) and (2). 
Odvojite po perforiranim crtama karticu s kapsulama po duljini i po širini, kako je prikazano na slikama (1) i (2).
• Vomiting, nausea 
• Povraćanje, mučninu
Each Podhaler device is only used for 7 days. 
Svaki se uređaj Podhaler koristi samo 7 dana.
Monthly pack. 
Mjesečno pakiranje.
Briefly inspect the inhaler to make sure it is not damaged or dirty. 
Kratko pregledajte inhalator kako biste provjerili da nije oštećen ili prljav.
• Store in the original packaging in order to protect from moisture. 
• Čuvati u originalnom pakiranju radi zaštite od vlage.
Based on available data from animals a risk of toxicity (e.g. ototoxicity) at prenatal exposure levels cannot be excluded. 
Na temelju podataka prikupljenih u ispitivanjima na životinjama, rizik od toksičnosti (npr. ototoksičnosti) za vrijeme prenatalne izloženosti lijeku ne može se isključiti.
Pharmacotherapeutic group: Antibacterials for systemic use, Aminoglycoside antibacterials, ATC Code: J01GB01 
Farmakoterapijska skupina: Antibakterijski lijekovi za sistemsku primjenu, Aminoglikozidni antibakterijski lijekovi, ATK oznaka: J01GB01
Inhale the powder deeply with a single breath. 
Duboko udahnite prašak jednim udisajem.
In case of missed dose with at least 6 hours until the next dose, the patient should take the dose as soon as possible. 
U slučaju propuštene doze pri čemu je do sljedeće doze ostalo najmanje 6 sati, bolesnik treba uzeti dozu čim bude moguće.
3 years Discard the Podhaler device and its case 1 week after first use. 
3 godine Bacite uređaj Podhaler i njegov spremnik tjedan dana nakon prve uporabe.
Non-clinical data reveal that the main hazard for humans, based on studies of safety pharmacology, repeated dose toxicity, genotoxicity, or toxicity to reproduction, consists of renal toxicity and ototoxicity. 
Neklinički podaci ukazuju da glavnu opasnost za ljude, na temelju ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti ili reproduktivne toksičnosti, predstavljaju bubrežna toksičnost i ototoksičnost.
Development of resistance during inhaled tobramycin therapy could limit treatment options during acute exacerbations; this should be monitored. 
Razvoj rezistencije tijekom inhalacijske terapije tobramicinom mogao bi ograničiti mogućnosti liječenja tijekom akutnih egzacerbacija; to se mora pratiti.
Do not use each inhaler and its case for longer than 1 week. 
Ne koristiti pojedini inhalator i njegov spremnik dulje od 1 tjedan.
• Look at the inhaler to make sure it is not damaged or dirty. 
• Pregledajte inhalator kako biste bili sigurni da nije oštećen ili prljav.
For safety results see section 4.8 
Za rezultate sigurnosti vidjeti 4.8.
The following medicines can increase the chances of harmful effects occurring if they are given to you while you are also receiving injections of tobramycin or other aminoglycoside antibiotic: 
Sljedeći lijekovi mogu povećati mogućnost pojave štetnih učinaka ako ih uzimate dok primate injekcije tobramicina ili drugog aminoglikozidnog antibiotika: